Supplementary Figure 7: Smoking status, tumor mutational burden, and clinical benefit from immune checkpoint therapy. | Nature Genetics

Supplementary Figure 7: Smoking status, tumor mutational burden, and clinical benefit from immune checkpoint therapy.

From: Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors

Supplementary Figure 7: Smoking status, tumor mutational burden, and clinical benefit from immune checkpoint therapy.

a, Proportion of patients with the smoking dominant mutational signature (S4, brown), APOBEC (S2/S13, teal), aging (S1, light tan), or unknown (S5, dark tan) by response group. b, Differences in mutational burden by response group in patients with a self-reported current/former smoking history (>5 pack-years). All P values reported are from two-sided Mann–Whitney U tests. CR/PR versus PD, P = 0.0002; CR/PR versus SD, P = 0.003; SD versus PD, P = 0.085. **P < 0.005 (two-sided Mann–Whitney U test). Box plots show the median, first and third quartiles, whiskers extend to 1.5 times the interquartile range, and outlying points are plotted individually.

Back to article page